| SIA "Centrālā laboratorija" Jelgavas filiālē (Brīvības bulvāris 6, Jelgava) veikto testu nenoteiktība - 2023. gadā | |||||
|---|---|---|---|---|---|
| Rādītājs | Analizators | Kopējā pieļaujamā nenoteiktība*, CV % | |||
| vidējais | |||||
| līmenis | |||||
| vid. | augsts | zems | |||
| Hematoloģija | |||||
| Leikocīti | Sysmex XN-1000 | 1.7 | 1.3 | 2.6 | 18 |
| Eritrocīti | 1.0 | 1.0 | 1.3 | 6 | |
| Hemoglobīns | 0.7 | 0.7 | 1.1 | 6 | |
| Hematokrīts | 1.6 | 1.5 | 1.7 | 9 | |
| MCV | 1.1 | 1.2 | 1.3 | 5 | |
| Trombocīti | 3.5 | 2.2 | 5.6 | 15 | |
| Neitrofīli (%) | 1.9 | 1.9 | 2.9 | 10 | |
| Limfocīti (%) | 2.0 | 1.9 | 2.8 | 10 | |
| Monocīti (%) | 4.0 | 3.4 | 5.7 | 30 | |
| Eozinofīli (%) | 7.1 | 6.7 | 7.4 | 30 | |
| Bazofīli (%) | 2.7 | 2.3 | 3.6 | 40 | |
| EGĀ | Roller 20 P | 4.24 | 2.76 | 6.33 | 30 |
| Hemostāze | |||||
| Protrombīns un INR | Sysmex CS-2500 | 4.36 | 4.81 | 5 | |
| APTL | 1.62 | 1.88 | 10 | ||
| D-dimēri | 6.46 | 7.63 | 10 | ||
| Fibrinogēns | 5.95 | 10 | |||
| Klīniskā ķīmija. Imūnķīmija | |||||
| Kopējais bilirubīns | Cobas Pure | 3.09 | 3.33 | ≤ 5.0 | |
| Tiešais bilirubīns | 2.75 | 2.89 | ≤ 5.0 | ||
| ALAT | 1.98 | 2.20 | ≤ 3.0 | ||
| ASAT | 1.98 | 1.85 | ≤ 3.0 | ||
| GGT | 1.51 | 1.65 | ≤ 4.0 | ||
| Amilāze | 1.70 | 1.85 | ≤ 3.0 | ||
| Sārmainā fosfotāze | 2.86 | 2.99 | ≤ 3.0 | ||
| Urīnviela | 2.33 | 2.54 | ≤ 3.0 | ||
| Kreatinīns | 2.20 | 2.87 | ≤ 5.0 | ||
| Urīnskābe | 1.57 | 1.69 | ≤ 3.0 | ||
| Kopējais olbaltums | 1.55 | 1.86 | ≤ 3.0 | ||
| Albumīns | 1.83 | 1.70 | ≤ 3.0 | ||
| Glikoze | 1.45 | 1.62 | ≤ 3.0 | ||
| Augsti jutīgs troponīns T | 2.15 | 2.46 | ≤6.0 | ||
| C-reaktīvais olbaltums | 2.77 | 2.41 | ≤ 5.0 | ||
| Reimatoīdais faktors | 2.15 | 2.15 | ≤ 6.0 | ||
| Nātrijs | 1.54 | 1.30 | ≤ 2.0 | ||
| Kālijs | 1.57 | 1.81 | ≤ 2.0 | ||
| Kalcijs | 1.68 | 1.29 | ≤ 3.0 | ||
| Neorganiskais fosfors | 1.43 | 1.60 | ≤ 3.0 | ||
| Dzelzs | 1.51 | 2.05 | ≤ 3.0 | ||
| Hlors | 1.48 | 1.59 | ≤ 2.0 | ||
| Kopējais holestrīns | 1.92 | 1.77 | ≤ 3.0 | ||
| ABL holesterīns | 3.23 | 2.52 | ≤ 6.0 | ||
| ZBL holesterīns | 2.22 | 1.94 | ≤ 3.0 | ||
| Triglicerīdi | 1.17 | 1.50 | ≤ 3.0 | ||
| TSH | 2.78 | 2.65 | ≤ 10.0 | ||
| Brīvais T4 | 1.95 | 1.47 | ≤ 8.0 | ||
| Hbs Ag | 4.99 | 9.66 | ≤ 10.0 | ||
| Etanols | 2.52 | 2.48 | ≤ 5.0 | ||
| Kopējais PSA | 2.93 | 2.56 | ≤ 5.4; ≤ 8.4 | ||
| Olbaltums urīnā | 0.39 | 1.32 | ≤4 | ||
| Kreatinīns urīnā | 1.53 | 1.47 | ≤ 5.0 | ||
| Glikoze urīnā | 0.81 | 1.27 | ≤3 | ||
| VIT D total III | 4.36 | 5.56 | ≤ 8 | ||
| Vitamīns B 12 II | 2.97 | 3.24 | ≤ 9.5 | ||
| Feritīns | 4.16 | 3.84 | ≤ 7.0 | ||
| Mikroalbumīns | 2.24 | 1.59 | ≤6 | ||
| Glikoze CSF | 1.13 | 1.20 | ≤ 3 | ||
| Olbaltums CSF | 0.46 | 1.28 | ≤ 4 | ||
| A1CX3 | 1.82 | 1.53 | ≤3 | ||
| Klīnika | |||||
| Urīna analīze ar stripu | Cobas u411 | 100% | |||
| Urīna analīze ar stripu | Cobas u6500 - u601 | 100% | |||
| RBC | u701 | 18.22 | < 1 | ≤ 20.0 | |
| WBC | 14.88 | < 1 | ≤ 20.0 | ||
| SIA "Centrālā laboratorija" Alūksnes filiāles (Vidus iela 1, Alūksne) veikto testu nenoteiktība 2023. gadā | ||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Tests | Iekārta | Nenoteiktība, CV% | Kopējā pieļaujamā nenoteiktība*, CV % | |||||||||||||||||||||||
| Vidējais līmenis Janvāris | Augstais līmenis Janvāris | Vidējais līmenis Februāris | Augstais līmenis Februāris | Vidējais līmenis Marts | Augstais līmenis Marts | Vidējais līmenis Aprīlis | Augstais līmenis Aprīlis | Vidējais līmenis Maijs | Augstais līmenis Maijs | Vidējais līmenis Jūnijs | Augstais līmenis Jūnijs | Vidējais līmenis Jūlijs | Augstais līmenis Jūlijs | Vidējais līmenis Augusts | Augstais līmenis Augusts | Vidējais līmenis Septembris | Augstais līmenis Septembris | Vidējais līmenis Oktobris | Augstais līmenis Oktobris | Vidējais līmenis Novembris | Augstais līmenis Novembris | Vidējais līmenis Decembris | Augstais līmenis Decembris | |||
| Hemostāze (SIEMENS BFT/II) | ||||||||||||||||||||||||||
| Protrombīns un INR | Siemens BFT II | 2.18 | 2.39 | 2.66 | 2.56 | 2.78 | 2.12 | 2.88 | 2.09 | 2.02 | 1.75 | 1.95 | 2.06 | - | - | - | - | - | - | - | - | - | - | - | - | < 3.0 |
| APTL | Siemens BFT II | 2.45 | 2.65 | 1.75 | 1.16 | 2.05 | 2.33 | 1.65 | 1.46 | 2.02 | 2.77 | 1.63 | 1.82 | - | - | - | - | - | - | - | - | - | - | - | - | < 3.0 |
| Bioķīmija (INTEGRA 400 Plus) | ||||||||||||||||||||||||||
| ALAT | Integra 400 Plus | 2.21 | 1.8 | 2.76 | 2.65 | 2.9 | 1.82 | 1.63 | 1.01 | - | 2.45 | 2.59 | 2.2 | 2.15 | 1.3 | 4.33 | 1.16 | 1.47 | 2.24 | 1.88 | 1.8 | 2.7 | 2.96 | 2.13 | 2.49 | < 4.0 |
| Tiešais bilirubīns | Integra 400 Plus | 3.03 | 2.42 | 1.99 | 3.03 | 1.88 | 2.92 | 3.01 | 2.12 | - | 3.09 | 3.34 | 4.08 | 3.61 | 2.91 | 2.89 | 2.07 | 2.07 | 2.09 | 3.09 | 2.15 | 3.14 | 3.68 | 2.38 | 2.89 | < 3.0 |
| Kopējais bilirubīns | Integra 400 Plus | 2.66 | m | 3.04 | 3 | 3.04 | 2.49 | 3.84 | 3.06 | - | 1.91 | 2.12 | 2.35 | 3.78 | 2.94 | 2.87 | 3.446 | 2.67 | 1.58 | 2.63 | 2.55 | 3.44 | 2.69 | 3.36 | 2.92 | < 3.0 |
| Kopējais holesterīns | Integra 400 Plus | 1.64 | 1.76 | 2.05 | 1.38 | 2.06 | 1.28 | 1.78 | 1.54 | - | 1.94 | 1.01 | 1.71 | 1.95 | 2.1 | 1.3 | 1.53 | 0.89 | 1.12 | 1.54 | 1.25 | 1.43 | 1.34 | 1.12 | 1.35 | < 3.0 |
| ABL holesterīns | Integra 400 Plus | 2.59 | 3.86 | 3.15 | 3.7 | 5.98 | 5.34 | 1.69 | 1.09 | - | 2.83 | 2.67 | 1.95 | 1.83 | 1.47 | 2.25 | 3.19 | 1.26 | 1.82 | 2.33 | 2.14 | 1.98 | 1.37 | 1.58 | 0.84 | < 5.0 |
| ZBL holesterīns | Integra 400 Plus | 3.69 | 3.22 | 3.28 | 3.92 | 2.2 | 2.11 | 1.94 | 1.46 | - | 1.84 | 1.79 | 2.63 | 2.21 | 3.04 | 3.44 | 2.36 | 1.38 | 1.05 | 1.88 | 1.12 | 2.33 | 2.24 | 1.89 | 2.14 | < 3.0 |
| Kreatinīns | Integra 400 Plus | 3.74 | 2.82 | 4.13 | 3.11 | 4.68 | 4.15 | 4.3 | 4.6 | - | 3.69 | 2.91 | 2.5 | 4.01 | 3.82 | 4.81 | 4.04 | 4.77 | 4.49 | 2.86 | 2.98 | 4 | 3.58 | 3.86 | 4.41 | < 5.0 |
| C reaktīvais olbaltums | Integra 400 Plus | 4.46 | 3.47 | 3.87 | 4.4 | 4.69 | 4.81 | 2.38 | 2.63 | - | 4.82 | 4.68 | 3.54 | 4.37 | 3.69 | 1.86 | 2.75 | 3.38 | 4.17 | 3.06 | 3.21 | 2.45 | 2.65 | 0.9 | 2.6 | < 5.0 |
| Glikoze | Integra 400 Plus | 1.47 | 1.77 | 1.83 | 1.84 | 1.44 | 1.3 | 1.5 | 1.29 | - | 2.01 | 0.52 | 0.77 | 0.93 | 1.87 | 1.58 | 0.82 | 0.64 | 0.83 | 2.61 | 1.98 | 2.54 | 2.28 | 2.5 | 2.61 | < 3.0 |
| Triglicerīdi | Integra 400 Plus | 2.51 | 2.03 | 1.18 | 1.59 | 3.03 | 2.39 | 1.04 | 1.18 | - | 2.58 | 1.69 | 2.34 | 0.6 | 1.58 | 1.06 | 1.06 | 1.77 | 1.82 | 1.29 | 1.1 | 0.79 | 0.6 | 2.37 | 2.22 | < 3.0 |
| Urīnviela | Integra 400 Plus | 3.59 | 1.08 | 3.3 | 1.55 | 4.37 | 3.6 | 3.17 | 3.2 | - | 2.66 | 1.62 | 2.54 | 3.02 | 3.03 | 3.04 | 2.36 | 2.08 | 2.25 | 2.41 | 1.62 | 3.75 | 2.8 | 2.49 | 1.49 | < 5.0 |
| ASAT | Integra 400 Plus | 2 | 1.94 | 1.47 | 1.09 | 2.44 | 3.16 | 2.92 | 2.25 | - | 2.11 | 1.96 | 2.71 | 1.32 | 1.52 | 2.19 | 1.56 | 1.24 | 1.26 | 1.95 | 1.21 | 0.73 | 0.5 | 0.79 | 1.22 | < 4.0 |
| SIA "Centrālā laboratorija" testēšanas filiāles veikto testu nenoteiktību kopsavilkums 2023. gadā | |||||
|---|---|---|---|---|---|
| Tests | Iekārta | Nenoteiktība, CV% | Kopējā pieļaujamā nenoteiktība*, CV % | ||
| Zemais līmenis | Vidējais līmenis | Augstais līmenis | |||
| Hemostāze | |||||
| Protrombīns | Sysmex CS 5100 | 4.99% | 4.5% | <5% | |
| INR | 2.9% | 3.8% | <5% | ||
| APTL | 1.6% | 3.5% | <5% | ||
| Fibrinogēns | 6.3% | 7.6% | <10% | ||
| Di -dimēri | 7.1% | 7.9% | <11% | ||
| Lupus antikoagulanti | Sysmex CS 2500 | 5.02% | <5% | ||
| Von Willebranda faktora Ag | 10% | <15% | |||
| VIII Faktora aktivitāte | 5.8% | <15% | |||
| IX Faktora aktivitāte | 5.3% | <15% | |||
| Trombīna laiks | 8.4% | <10% | |||
| Antitrombīns III | 8.2% | <10% | |||
| Proteīna C aktivitāte | 8.7% | <15% | |||
| Brīvā Proteīna S Ag | 2.5% | <10% | |||
| Rezistence pret aktivēto proteīnu C | 5.7% | <10% | |||
| Klīniskā ķīmija un imūnķīmija | |||||
| BNP (B tipa nātrijurētiskais peptīds) | Abbott Architect i2000SR | 5.4% | 6.8% | 3.02% | ≤12% |
| Mioglobīns | 7% | 10% | ≤10% | ||
| Anti-SARS-CoV-2 IgG | 9.8% | 5.9% | ≤10% | ||
| Sifilisa imūnfermentatīvā analīze IgG, IgM | 10% | 6.8% | ≤15% | ||
| Anti Hbc IgM | 12.7% | 4.9% | ≤14% | ||
| Hepatīta C antigēns | 4.9% | 9.6% | ≤10% | ||
| SCC | 4.9% | 3.4% | ≤10% | ||
| Anti Epšteina-Barra vīrusa VCA IgM | Abbott Alinity ci | 7.14% | ≤13% | ||
| Anti Epšteina-Barra vīrusa VCA IgG | 8.65% | ≤13% | |||
| Anti Toxoplasma gondii IgM | 10.08% | 4.10% | ≤10% | ||
| Anti Toxoplasma gondii IgG | 7.62% | 4.62% | ≤10% | ||
| Anti citomegalovīrusa (CMV) IgM AV | 13% | ≤10% | |||
| Anti citomegalovīrusa (CMV) IgG AV | 4.35% | 4.36% | ≤10% | ||
| Anti HBs (pote) | 6.35% | 3.3% | ≤13% | ||
| Anti Hbc | 8.45% | 7.3% | ≤12% | ||
| Hepatīta C antivielas | 8% | 7.5% | ≤8% | ||
| HbsAg | 2.75% | ≤10% | |||
| HIV Ag/Ab | 10.14% | 8.55% | 5.30% | ≤14% | |
| Hepatīta A IgM AV | 9.74% | 10% | ≤10% | ||
| Insulīns | 5.78% | 4.65% | 4.24% | ≤6% | |
| CEA | 8.3% | 5.4% | 6.3% | ≤10.5% | |
| CA 19-9 | 7.8% | 6.1% | 6.8% | ≤9% | |
| CA 15-3 | 4.4% | 4.7% | ≤7.5% | ||
| Anti-Tg | 9.3% | ≤10% | |||
| Anti-TPO | 9.0% | ≤12% | |||
| B 12 vitamīns | 11% | 9.0% | ≤11% | ||
| Folskābe | 7.72% | 6.71% | 9.37% | ≤12% | |
| Homocisteīns | 6.91% | 8.12% | 5.35% | ≤10% | |
| IL-6 | Immulite 2000 Xpi | 6.49% | 7% | ≤ 7% | |
| AKTH | 8.86% | 7.05% | ≤ 10 % | ||
| STH | 6.80% | 6.61% | ≤ 10 % | ||
| Kopējais IgE | 12.08% | 12.7% | ≤ 13 % | ||
| Specifiskie IgE | 9.30% | 11% | ≤ 13 % | ||
| ECP | 10.06% | 11.5% | ≤ 12 % | ||
| IGF | 4.99% | 5.75% | ≤ 10 % | ||
| Brīvais Estriols | 9.22% | 7.89% | ≤ 12 % | ||
| Tireoglobulīns | 14.7% | 13.1% | 11.7% | ≤ 15% | |
| Alfa fetoproteīns | 6.25% | 7.06% | ≤ 10 % | ||
| HCG | 10.01% | 9.39% | ≤ 10 % | ||
| Eritropoetīns | 9.66% | 8.19% | 7.70% | ≤ 10 % | |
| HbA1C | Roche Cobas Pure | 2.0 % | 2.03% | ≤3% | |
| NSE | 3.09% | 4.17% | ≤6.5% | ||
| CA 72-4 | 3.69% | 3.09% | ≤6% | ||
| Osteokalcīns | 2.33% | 3.23% | ≤4% | ||
| P1NP | 7.13% | 4.91% | ≤7% | ||
| CrossLaps | 4.17% | 4.02% | ≤5% | ||
| S100 | 3.08% | 2.91% | ≤5% | ||
| Anti-Millera hormons | 3.19% | 3.43% | ≤5% | ||
| PLGF | 4.01% | 2.49% | ≤ 8% | ||
| TRANSFERĪNS | Roche Cobas PRO 1 | 1.96% | 2.20% | ≤6% | |
| Beta-2 mikroglobulīns | 2.69% | 4.26% | ≤6% | ||
| Lipoprpteīns a | 6.07% | 5.49% | ≤6% | ||
| Dzelzs saistīšanas spēja | 2.67% | 3.00% | ≤5% | ||
| Kreatinīns | 2.96% | 3.90% | ≤5% | ||
| Kreatinīns urīnā | 1.58% | 1.71% | ≤5% | ||
| Glikoze | 1.93% | 1.23% | ≤3% | ||
| Glikoze urīnā | 1.44% | 0.73% | ≤3% | ||
| Glikoze likvorā | 1.03% | 0.89% | ≤3% | ||
| B12aktīvais | 4.73% | 3.93% | ≤6% | ||
| AAT | 4.70% | 4.54% | ≤6% | ||
| SKABĀ FOSFOTĀZE | 5.12% | 3.13% | ≤5% | ||
| ALBUMĪNS | 1.80% | 1.54% | ≤3% | ||
| MIKROALBUMĪNS (URĪNS) | 4.72% | 1.73% | ≤6% | ||
| OLBALTUMS URĪNĀ | 3.30% | 3.35% | ≤4% | ||
| OLBALTUMS LIKVORĀ | 2.57% | 2.79% | ≤4% | ||
| IgG | 1.19% | 1.54% | ≤6% | ||
| IgM | 4.92% | 5.48% | ≤6% | ||
| IgA | 1.80% | 1.50% | ≤6% | ||
| CISTATĪNS C | 5.63% | 6.05% | 4.91% | ≤6% | |
| APOLIPOPROTEĪNS A1 | 4.13% | 4.71% | ≤6% | ||
| APOLIPOPROTEĪNS B | 3.94% | 3.47% | ≤6% | ||
| KOMPLEMENTA FAKTORS C3 | 2.57% | 2.75% | ≤6% | ||
| KOMPLEMENTA FAKTORS C4 | 3.84% | 2.42% | ≤6% | ||
| AUGSTI JUTĪGS CRO | 1.92% | ≤5% | |||
| CERULOPLAZMĪNS | 3.48% | 2.50% | ≤6% | ||
| Kreatīnkināzes MB frakcija (CK-MB) | 1.86% | 1.55% | ≤5% | ||
| CA 125 | 4.80% | 3.33% | ≤8% | ||
| CYFRA 21-1 | 3.59% | 5.04% | ≤6.5% | ||
| HE4 | 7.03% | 6.45% | ≤7% | ||
| T3 | 6.05% | 4.37% | ≤6% | ||
| T4 | 4.09% | 3.97% | ≤4% | ||
| Anti-TSHR | 6.54% | ≤7% | |||
| Kalcitonīns | 4.38% | 3.28% | ≤6% | ||
| pro BNP | 3.47% | 3.29% | ≤5% | ||
| Cortisol II serum | 4.39% | 3.58% | ≤ 6% | ||
| Cortisol II saliva | 6.15% | 6.02% | ≤ 6% | ||
| DHEAS | 7.19% | 5.31% | ≤ 7% | ||
| FSH | 3.85% | 2.67% | ≤ 5.1% | ||
| LH | 3.31% | 2.48% | ≤ 5% | ||
| C-Peptīds | 3.13% | 4.92% | ≤ 6% | ||
| Free ßhCG | 4.40% | 4.96% | 4.41% | ≤ 5% | |
| SHBG | 4.14% | 3.66% | ≤ 6% | ||
| PAPP-A | 5.02% | 5.16% | 5.08% | ≤ 5% | |
| Prolaktīns | 3.87% | 2.95% | ≤ 7% | ||
| Anti-CCP | 8.0% | 4.4% | ≤ 8% | ||
| Prokalcitonīns | 2.52% | 3.34% | ≤ 15% | ||
| Ciklosporīns | 9.35% | 9.16% | 10.19% | ≤10% | |
| Tacrolimus | 6.06% | 6.05% | 5.99% | ≤ 6% | |
| SFLT | 2.02% | 3.30% | ≤ 7% | ||
| FT3 | Roche Cobas PRO 2 | 6.29% | 5.46% | ≤8% | |
| FT4 | 2.85% | 3.36% | ≤8% | ||
| TSH | 4.17% | 3.85% | ≤10% | ||
| Troponīns T | 2.38% | 3.21% | ≤6% | ||
| hCG STAT | 5.54% | 5.12% | ≤5.6% | ||
| Androstenedione | 7.91% | 6.43% | 7.02% | ≤ 8.0 % | |
| Estradiol | 6.39% | 6.11% | ≤ 8% | ||
| Progesterons | 5.64% | 5.87% | ≤ 7% | ||
| Testosterons | 5.50% | 5.33% | ≤ 6% | ||
| PSA | 5.06% | 4.98% | ≤ 5.4% | ||
| Feritīns | 6.55% | 5.30% | ≤ 7% | ||
| PTH | 5.27% | 5.47% | ≤ 6% | ||
| Vitamin D total | 7.61% | 7.17% | ≤ 8% | ||
| ALAT | 1.54% | 2.30% | ≤4% | ||
| ASAT | 1.49% | 1.25% | ≤4% | ||
| KOPĒJAIS BILIRUBĪNS | 3.88% | 2.89% | ≤5% | ||
| TIEŠAIS BILIRUBĪNS | 2.45% | 2.88% | ≤5% | ||
| GGT | 1.36% | 1.38% | ≤4% | ||
| SĀRMAINĀ FOSFOTĀZE | 3.0% | 2.55% | ≤3% | ||
| LDH | 1.10% | 1.18% | ≤3% | ||
| LIPĀZE | 1.94% | 2.21% | ≤3% | ||
| ALFA AMILĀZE | 1.24% | 1.48% | ≤3% | ||
| Amilāze, urīns | 1.09% | 1.04% | ≤3% | ||
| PSEIDOHOLĪNESTERĀZE | 1.01% | 1.37% | ≤4% | ||
| KREATĪNKINĀZE | 2.28% | 1.32% | ≤4% | ||
| KOPĒJAIS OLBALTUMS | 1.10% | 1.30% | ≤3% | ||
| URĪNVIELA | 2.63% | 2.39% | ≤3% | ||
| Urīnviela urīns | 3.03% | 2.69% | ≤3% | ||
| KREATINĪNS | 2.16% | 2.42% | ≤5% | ||
| Kreatinīns, urīns | 2.14% | 2.31% | ≤5% | ||
| URĪNSKĀBE | 1.06% | 1.11% | ≤3% | ||
| Urīnskābe urīns | 2.21% | 1.58% | ≤3% | ||
| GLIKOZE | 0.89% | 1.13% | ≤3% | ||
| Glikoze, urīns | 1.72% | 0.92% | ≤3% | ||
| NĀTRIJS | 0.98% | 0.74% | ≤2% | ||
| Nātrijs, urīnā | 1.47% | 0.83% | ≤2% | ||
| KĀLIJS | 1.44% | 0.65% | ≤2% | ||
| Kālijs,urīnā | 1.97% | 1.99% | ≤2% | ||
| HLORĪDI | 1.21% | 1.18% | ≤2% | ||
| Hlors,urīnā | 1.54% | 1.66% | ≤2% | ||
| MAGNIJS | 0.72% | 0.92% | ≤3% | ||
| Magnijs, urīns | 1.44% | 2.76% | ≤3% | ||
| KALCIJS | 0.84% | 1.81% | ≤3% | ||
| Kalcijs, urīns | 1.61% | 0.85% | ≤3% | ||
| FOSFORS NEORGANISKAIS | 1.36% | 1.15% | ≤3% | ||
| Fosfors,urīns | 1.91% | 1.36% | ≤3% | ||
| KOPĒJAIS HOLESTERĪNS | 2.41% | 1.81% | ≤3% | ||
| ABL HOLESTERĪNS | 1.64% | 1.95% | ≤6% | ||
| ZBL HOLESTERĪNS | 2.51% | 1.52% | ≤3% | ||
| TRIGLICERĪDI | 0.99% | 1.41% | ≤3% | ||
| C REAKTĪVAIS OLBALTUMS | 3.98% | 4.06% | ≤5% | ||
| REIMATOĪDAIS FAKTORS | 4.35% | 2.35% | ≤6% | ||
| ANTISTREPTOLIZĪNS O | 2.03% | 2.11% | ≤6% | ||
| DZELZS | 2.21% | 1.96% | ≤3% | ||
| FT3 | Roche Cobas PRO 3 | 4.27% | 3.49% | ≤8% | |
| FT4 | 2.85% | 3.36% | ≤8% | ||
| TSH | 4.17% | 3.85% | ≤10% | ||
| Troponīns T | 2.61% | 2.27% | ≤6% | ||
| hCG STAT | 5.54% | 5.12% | ≤5.6% | ||
| Androstenedione | 7.59% | 6.57% | 7.77% | ≤8% | |
| Estradiol | 6.78% | 3.58% | ≤ 8% | ||
| Progesterons | 5.09% | 5.14% | ≤ 7% | ||
| Testosterons | 4.56% | 4.27% | ≤ 6% | ||
| PSA | 4.08% | 4.38% | ≤ 5.4% | ||
| fPSA | 4.91% | 5.02% | ≤ 8.4% | ||
| Feritīns | 5.17% | 6.70% | ≤ 7% | ||
| PTH | 5.05% | 4.55% | ≤ 6% | ||
| Vitamin D total | 5.73% | 5.22% | ≤ 8% | ||
| ALAT | 1.42% | 2.62% | ≤4% | ||
| ASAT | 1.56% | 1.59% | ≤4% | ||
| KOPĒJAIS BILIRUBĪNS | 2.61% | 2.93% | ≤5% | ||
| TIEŠAIS BILIRUBĪNS | 2.79% | 3.71% | ≤5% | ||
| GGT | 1.19% | 1.33% | ≤4% | ||
| SĀRMAINĀ FOSFOTĀZE | 2.98% | 2.84% | ≤3% | ||
| LDH | 1.13% | 1.24% | ≤3% | ||
| LIPĀZE | 1.97% | 1.86% | ≤3% | ||
| ALFA AMILĀZE | 1.46% | 1.90% | ≤3% | ||
| KREATĪNKINĀZE | 1.37% | 1.27% | ≤4% | ||
| KOPĒJAIS OLBALTUMS | 1.26% | 1.46% | ≤3% | ||
| URĪNVIELA | 1.64% | 1.59% | ≤3% | ||
| KREATINĪNS | 2.81% | 3.02% | ≤5% | ||
| URĪNSKĀBE | 1.35% | 1.35% | ≤3% | ||
| GLIKOZE | 0.91% | 1.10% | ≤3% | ||
| NĀTRIJS | 1.36% | 1.19% | ≤2% | ||
| KĀLIJS | 1.98% | 1.27% | ≤2% | ||
| HLORĪDI | 1.98% | 1.88% | ≤2% | ||
| MAGNIJS | 1.15% | 1.23% | ≤3% | ||
| KALCIJS | 1.08% | 1.28% | ≤3% | ||
| FOSFORS NEORGANISKAIS | 1.30% | 1.29% | ≤3% | ||
| KOPĒJAIS HOLESTERĪNS | 2.04% | 2.37% | ≤3% | ||
| ABL HOLESTERĪNS | 1.61% | 1.78% | ≤6% | ||
| ZBL HOLESTERĪNS | 1.42% | 1.48% | ≤3% | ||
| TRIGLICERĪDI | 1.24% | 1.35% | ≤3% | ||
| C REAKTĪVAIS OLBALTUMS | 2.28% | 2.12% | ≤5% | ||
| REIMATOĪDAIS FAKTORS | 2.38% | 1.83% | ≤6% | ||
| ANTISTREPTOLIZĪNS O | 2.68% | 2.41% | ≤6% | ||
| DZELZS | 0.93% | 1.15% | ≤3% | ||
Informācija aktualizēta 13.03.2025.
Nenoteiktību reģistrs
- Rīgas filiāles (Miera iela 45, Rīga) veikto testu nenoteiktība kvantitatīvajām metodēm 2024. gadā
- Rīgas filiāles (Gredu iela 4, Rīga) veikto testu nenoteiktība kvantitatīvajām metodēm 2024. gadā
- Alūksne filiāles (Vidus iela 1, Alūksne) veikto testu nenoteiktība kvantitatīvajām metodēm 2024. gadā
- Jelgavas filiāles (Brīvības bulvāris 6, Jelgava) veikto testu nenoteiktība kvantitatīvajām metodēm 2024. gadā
- Saldus filiāles (Slimnīcas iela 3, Saldus) veikto testu nenoteiktība kvantitatīvajām metodēm 2024. gadā
- Rēzeknes filiāles (18. Novembra iela 41 , Rēzekne) veikto testu nenoteiktība kvantitatīvajām metodēm 2024. gadā
- Krāslavas filiāles (Rīgas iela 159, Krāslava) veikto testu nenoteiktība kvantitatīvajām metodēm 2024. gadā
- Balvu filiāles (Krasta iela 1b) veikto testu nenoteiktība kvantitatīvajām metodēm 2024. gadā
- Liepājas filiāles (Slimnīcas iela 25, Liepāja) veikto testu nenoteiktība kvantitatīvajām metodēm 2024. gadā
- Vecliepājas filiāles (Republikas iela 5, Liepāja) veikto testu nenoteiktība kvantitatīvajām metodēm 2024. gadā
- Madonas filiāles (Rūpniecības iela 38, Madona) veikto testu nenoteiktība kvantitatīvajām metodēm 2024. gadā
- Cēsis filiāles (Slimnīcas iela 9, Cēsis) veikto testu nenoteiktība kvantitatīvajām metodēm 2024. gadā
Testēšanas metožu saraksts
Informācija aktualizēta 26.01.2023.
.
Informācija aktualizēta 26.01.2023.
.
| SIA "Centrālā laboratorija" testēšanas filiāles veikto testu nenoteiktību kopsavilkums 2023. gadā | |||||
|---|---|---|---|---|---|
| Tests | Iekārta | Nenoteiktība, CV% | Kopējā pieļaujamā nenoteiktība*, CV % | ||
| Zemais līmenis | Vidējais līmenis | Augstais līmenis | |||
| Hemostāze | |||||
| Protrombīns | Sysmex CS 5100 | 4.99% | 4.5% | <5% | |
| INR | 2.9% | 3.8% | <5% | ||
| APTL | 1.6% | 3.5% | <5% | ||
| Fibrinogēns | 6.3% | 7.6% | <10% | ||
| Di -dimēri | 7.1% | 7.9% | <11% | ||
| Lupus antikoagulanti | Sysmex CS 2500 | 5.02% | <5% | ||
| Von Willebranda faktora Ag | 10% | <15% | |||
| VIII Faktora aktivitāte | 5.8% | <15% | |||
| IX Faktora aktivitāte | 5.3% | <15% | |||
| Trombīna laiks | 8.4% | <10% | |||
| Antitrombīns III | 8.2% | <10% | |||
| Proteīna C aktivitāte | 8.7% | <15% | |||
| Brīvā Proteīna S Ag | 2.5% | <10% | |||
| Rezistence pret aktivēto proteīnu C | 5.7% | <10% | |||
| Klīniskā ķīmija un imūnķīmija | |||||
| BNP (B tipa nātrijurētiskais peptīds) | Abbott Architect i2000SR | 5.4% | 6.8% | 3.02% | ≤12% |
| Mioglobīns | 7% | 10% | ≤10% | ||
| Anti-SARS-CoV-2 IgG | 9.8% | 5.9% | ≤10% | ||
| Sifilisa imūnfermentatīvā analīze IgG, IgM | 10% | 6.8% | ≤15% | ||
| Anti Hbc IgM | 12.7% | 4.9% | ≤14% | ||
| Hepatīta C antigēns | 4.9% | 9.6% | ≤10% | ||
| SCC | 4.9% | 3.4% | ≤10% | ||
| Anti Epšteina-Barra vīrusa VCA IgM | Abbott Alinity ci | 7.14% | ≤13% | ||
| Anti Epšteina-Barra vīrusa VCA IgG | 8.65% | ≤13% | |||
| Anti Toxoplasma gondii IgM | 10.08% | 4.10% | ≤10% | ||
| Anti Toxoplasma gondii IgG | 7.62% | 4.62% | ≤10% | ||
| Anti citomegalovīrusa (CMV) IgM AV | 13% | ≤10% | |||
| Anti citomegalovīrusa (CMV) IgG AV | 4.35% | 4.36% | ≤10% | ||
| Anti HBs (pote) | 6.35% | 3.3% | ≤13% | ||
| Anti Hbc | 8.45% | 7.3% | ≤12% | ||
| Hepatīta C antivielas | 8% | 7.5% | ≤8% | ||
| HbsAg | 2.75% | ≤10% | |||
| HIV Ag/Ab | 10.14% | 8.55% | 5.30% | ≤14% | |
| Hepatīta A IgM AV | 9.74% | 10% | ≤10% | ||
| Insulīns | 5.78% | 4.65% | 4.24% | ≤6% | |
| CEA | 8.3% | 5.4% | 6.3% | ≤10.5% | |
| CA 19-9 | 7.8% | 6.1% | 6.8% | ≤9% | |
| CA 15-3 | 4.4% | 4.7% | ≤7.5% | ||
| Anti-Tg | 9.3% | ≤10% | |||
| Anti-TPO | 9.0% | ≤12% | |||
| B 12 vitamīns | 11% | 9.0% | ≤11% | ||
| Folskābe | 7.72% | 6.71% | 9.37% | ≤12% | |
| Homocisteīns | 6.91% | 8.12% | 5.35% | ≤10% | |
| IL-6 | Immulite 2000 Xpi | 6.49% | 7% | ≤ 7% | |
| AKTH | 8.86% | 7.05% | ≤ 10 % | ||
| STH | 6.80% | 6.61% | ≤ 10 % | ||
| Kopējais IgE | 12.08% | 12.7% | ≤ 13 % | ||
| Specifiskie IgE | 9.30% | 11% | ≤ 13 % | ||
| ECP | 10.06% | 11.5% | ≤ 12 % | ||
| IGF | 4.99% | 5.75% | ≤ 10 % | ||
| Brīvais Estriols | 9.22% | 7.89% | ≤ 12 % | ||
| Tireoglobulīns | 14.7% | 13.1% | 11.7% | ≤ 15% | |
| Alfa fetoproteīns | 6.25% | 7.06% | ≤ 10 % | ||
| HCG | 10.01% | 9.39% | ≤ 10 % | ||
| Eritropoetīns | 9.66% | 8.19% | 7.70% | ≤ 10 % | |
| HbA1C | Roche Cobas Pure | 2.0 % | 2.03% | ≤3% | |
| NSE | 3.09% | 4.17% | ≤6.5% | ||
| CA 72-4 | 3.69% | 3.09% | ≤6% | ||
| Osteokalcīns | 2.33% | 3.23% | ≤4% | ||
| P1NP | 7.13% | 4.91% | ≤7% | ||
| CrossLaps | 4.17% | 4.02% | ≤5% | ||
| S100 | 3.08% | 2.91% | ≤5% | ||
| Anti-Millera hormons | 3.19% | 3.43% | ≤5% | ||
| PLGF | 4.01% | 2.49% | ≤ 8% | ||
| TRANSFERĪNS | Roche Cobas PRO 1 | 1.96% | 2.20% | ≤6% | |
| Beta-2 mikroglobulīns | 2.69% | 4.26% | ≤6% | ||
| Lipoprpteīns a | 6.07% | 5.49% | ≤6% | ||
| Dzelzs saistīšanas spēja | 2.67% | 3.00% | ≤5% | ||
| Kreatinīns | 2.96% | 3.90% | ≤5% | ||
| Kreatinīns urīnā | 1.58% | 1.71% | ≤5% | ||
| Glikoze | 1.93% | 1.23% | ≤3% | ||
| Glikoze urīnā | 1.44% | 0.73% | ≤3% | ||
| Glikoze likvorā | 1.03% | 0.89% | ≤3% | ||
| B12aktīvais | 4.73% | 3.93% | ≤6% | ||
| AAT | 4.70% | 4.54% | ≤6% | ||
| SKABĀ FOSFOTĀZE | 5.12% | 3.13% | ≤5% | ||
| ALBUMĪNS | 1.80% | 1.54% | ≤3% | ||
| MIKROALBUMĪNS (URĪNS) | 4.72% | 1.73% | ≤6% | ||
| OLBALTUMS URĪNĀ | 3.30% | 3.35% | ≤4% | ||
| OLBALTUMS LIKVORĀ | 2.57% | 2.79% | ≤4% | ||
| IgG | 1.19% | 1.54% | ≤6% | ||
| IgM | 4.92% | 5.48% | ≤6% | ||
| IgA | 1.80% | 1.50% | ≤6% | ||
| CISTATĪNS C | 5.63% | 6.05% | 4.91% | ≤6% | |
| APOLIPOPROTEĪNS A1 | 4.13% | 4.71% | ≤6% | ||
| APOLIPOPROTEĪNS B | 3.94% | 3.47% | ≤6% | ||
| KOMPLEMENTA FAKTORS C3 | 2.57% | 2.75% | ≤6% | ||
| KOMPLEMENTA FAKTORS C4 | 3.84% | 2.42% | ≤6% | ||
| AUGSTI JUTĪGS CRO | 1.92% | ≤5% | |||
| CERULOPLAZMĪNS | 3.48% | 2.50% | ≤6% | ||
| Kreatīnkināzes MB frakcija (CK-MB) | 1.86% | 1.55% | ≤5% | ||
| CA 125 | 4.80% | 3.33% | ≤8% | ||
| CYFRA 21-1 | 3.59% | 5.04% | ≤6.5% | ||
| HE4 | 7.03% | 6.45% | ≤7% | ||
| T3 | 6.05% | 4.37% | ≤6% | ||
| T4 | 4.09% | 3.97% | ≤4% | ||
| Anti-TSHR | 6.54% | ≤7% | |||
| Kalcitonīns | 4.38% | 3.28% | ≤6% | ||
| pro BNP | 3.47% | 3.29% | ≤5% | ||
| Cortisol II serum | 4.39% | 3.58% | ≤ 6% | ||
| Cortisol II saliva | 6.15% | 6.02% | ≤ 6% | ||
| DHEAS | 7.19% | 5.31% | ≤ 7% | ||
| FSH | 3.85% | 2.67% | ≤ 5.1% | ||
| LH | 3.31% | 2.48% | ≤ 5% | ||
| C-Peptīds | 3.13% | 4.92% | ≤ 6% | ||
| Free ßhCG | 4.40% | 4.96% | 4.41% | ≤ 5% | |
| SHBG | 4.14% | 3.66% | ≤ 6% | ||
| PAPP-A | 5.02% | 5.16% | 5.08% | ≤ 5% | |
| Prolaktīns | 3.87% | 2.95% | ≤ 7% | ||
| Anti-CCP | 8.0% | 4.4% | ≤ 8% | ||
| Prokalcitonīns | 2.52% | 3.34% | ≤ 15% | ||
| Ciklosporīns | 9.35% | 9.16% | 10.19% | ≤10% | |
| Tacrolimus | 6.06% | 6.05% | 5.99% | ≤ 6% | |
| SFLT | 2.02% | 3.30% | ≤ 7% | ||
| FT3 | Roche Cobas PRO 2 | 6.29% | 5.46% | ≤8% | |
| FT4 | 2.85% | 3.36% | ≤8% | ||
| TSH | 4.17% | 3.85% | ≤10% | ||
| Troponīns T | 2.38% | 3.21% | ≤6% | ||
| hCG STAT | 5.54% | 5.12% | ≤5.6% | ||
| Androstenedione | 7.91% | 6.43% | 7.02% | ≤ 8.0 % | |
| Estradiol | 6.39% | 6.11% | ≤ 8% | ||
| Progesterons | 5.64% | 5.87% | ≤ 7% | ||
| Testosterons | 5.50% | 5.33% | ≤ 6% | ||
| PSA | 5.06% | 4.98% | ≤ 5.4% | ||
| Feritīns | 6.55% | 5.30% | ≤ 7% | ||
| PTH | 5.27% | 5.47% | ≤ 6% | ||
| Vitamin D total | 7.61% | 7.17% | ≤ 8% | ||
| ALAT | 1.54% | 2.30% | ≤4% | ||
| ASAT | 1.49% | 1.25% | ≤4% | ||
| KOPĒJAIS BILIRUBĪNS | 3.88% | 2.89% | ≤5% | ||
| TIEŠAIS BILIRUBĪNS | 2.45% | 2.88% | ≤5% | ||
| GGT | 1.36% | 1.38% | ≤4% | ||
| SĀRMAINĀ FOSFOTĀZE | 3.0% | 2.55% | ≤3% | ||
| LDH | 1.10% | 1.18% | ≤3% | ||
| LIPĀZE | 1.94% | 2.21% | ≤3% | ||
| ALFA AMILĀZE | 1.24% | 1.48% | ≤3% | ||
| Amilāze, urīns | 1.09% | 1.04% | ≤3% | ||
| PSEIDOHOLĪNESTERĀZE | 1.01% | 1.37% | ≤4% | ||
| KREATĪNKINĀZE | 2.28% | 1.32% | ≤4% | ||
| KOPĒJAIS OLBALTUMS | 1.10% | 1.30% | ≤3% | ||
| URĪNVIELA | 2.63% | 2.39% | ≤3% | ||
| Urīnviela urīns | 3.03% | 2.69% | ≤3% | ||
| KREATINĪNS | 2.16% | 2.42% | ≤5% | ||
| Kreatinīns, urīns | 2.14% | 2.31% | ≤5% | ||
| URĪNSKĀBE | 1.06% | 1.11% | ≤3% | ||
| Urīnskābe urīns | 2.21% | 1.58% | ≤3% | ||
| GLIKOZE | 0.89% | 1.13% | ≤3% | ||
| Glikoze, urīns | 1.72% | 0.92% | ≤3% | ||
| NĀTRIJS | 0.98% | 0.74% | ≤2% | ||
| Nātrijs, urīnā | 1.47% | 0.83% | ≤2% | ||
| KĀLIJS | 1.44% | 0.65% | ≤2% | ||
| Kālijs,urīnā | 1.97% | 1.99% | ≤2% | ||
| HLORĪDI | 1.21% | 1.18% | ≤2% | ||
| Hlors,urīnā | 1.54% | 1.66% | ≤2% | ||
| MAGNIJS | 0.72% | 0.92% | ≤3% | ||
| Magnijs, urīns | 1.44% | 2.76% | ≤3% | ||
| KALCIJS | 0.84% | 1.81% | ≤3% | ||
| Kalcijs, urīns | 1.61% | 0.85% | ≤3% | ||
| FOSFORS NEORGANISKAIS | 1.36% | 1.15% | ≤3% | ||
| Fosfors,urīns | 1.91% | 1.36% | ≤3% | ||
| KOPĒJAIS HOLESTERĪNS | 2.41% | 1.81% | ≤3% | ||
| ABL HOLESTERĪNS | 1.64% | 1.95% | ≤6% | ||
| ZBL HOLESTERĪNS | 2.51% | 1.52% | ≤3% | ||
| TRIGLICERĪDI | 0.99% | 1.41% | ≤3% | ||
| C REAKTĪVAIS OLBALTUMS | 3.98% | 4.06% | ≤5% | ||
| REIMATOĪDAIS FAKTORS | 4.35% | 2.35% | ≤6% | ||
| ANTISTREPTOLIZĪNS O | 2.03% | 2.11% | ≤6% | ||
| DZELZS | 2.21% | 1.96% | ≤3% | ||
| FT3 | Roche Cobas PRO 3 | 4.27% | 3.49% | ≤8% | |
| FT4 | 2.85% | 3.36% | ≤8% | ||
| TSH | 4.17% | 3.85% | ≤10% | ||
| Troponīns T | 2.61% | 2.27% | ≤6% | ||
| hCG STAT | 5.54% | 5.12% | ≤5.6% | ||
| Androstenedione | 7.59% | 6.57% | 7.77% | ≤8% | |
| Estradiol | 6.78% | 3.58% | ≤ 8% | ||
| Progesterons | 5.09% | 5.14% | ≤ 7% | ||
| Testosterons | 4.56% | 4.27% | ≤ 6% | ||
| PSA | 4.08% | 4.38% | ≤ 5.4% | ||
| fPSA | 4.91% | 5.02% | ≤ 8.4% | ||
| Feritīns | 5.17% | 6.70% | ≤ 7% | ||
| PTH | 5.05% | 4.55% | ≤ 6% | ||
| Vitamin D total | 5.73% | 5.22% | ≤ 8% | ||
| ALAT | 1.42% | 2.62% | ≤4% | ||
| ASAT | 1.56% | 1.59% | ≤4% | ||
| KOPĒJAIS BILIRUBĪNS | 2.61% | 2.93% | ≤5% | ||
| TIEŠAIS BILIRUBĪNS | 2.79% | 3.71% | ≤5% | ||
| GGT | 1.19% | 1.33% | ≤4% | ||
| SĀRMAINĀ FOSFOTĀZE | 2.98% | 2.84% | ≤3% | ||
| LDH | 1.13% | 1.24% | ≤3% | ||
| LIPĀZE | 1.97% | 1.86% | ≤3% | ||
| ALFA AMILĀZE | 1.46% | 1.90% | ≤3% | ||
| KREATĪNKINĀZE | 1.37% | 1.27% | ≤4% | ||
| KOPĒJAIS OLBALTUMS | 1.26% | 1.46% | ≤3% | ||
| URĪNVIELA | 1.64% | 1.59% | ≤3% | ||
| KREATINĪNS | 2.81% | 3.02% | ≤5% | ||
| URĪNSKĀBE | 1.35% | 1.35% | ≤3% | ||
| GLIKOZE | 0.91% | 1.10% | ≤3% | ||
| NĀTRIJS | 1.36% | 1.19% | ≤2% | ||
| KĀLIJS | 1.98% | 1.27% | ≤2% | ||
| HLORĪDI | 1.98% | 1.88% | ≤2% | ||
| MAGNIJS | 1.15% | 1.23% | ≤3% | ||
| KALCIJS | 1.08% | 1.28% | ≤3% | ||
| FOSFORS NEORGANISKAIS | 1.30% | 1.29% | ≤3% | ||
| KOPĒJAIS HOLESTERĪNS | 2.04% | 2.37% | ≤3% | ||
| ABL HOLESTERĪNS | 1.61% | 1.78% | ≤6% | ||
| ZBL HOLESTERĪNS | 1.42% | 1.48% | ≤3% | ||
| TRIGLICERĪDI | 1.24% | 1.35% | ≤3% | ||
| C REAKTĪVAIS OLBALTUMS | 2.28% | 2.12% | ≤5% | ||
| REIMATOĪDAIS FAKTORS | 2.38% | 1.83% | ≤6% | ||
| ANTISTREPTOLIZĪNS O | 2.68% | 2.41% | ≤6% | ||
| DZELZS | 0.93% | 1.15% | ≤3% | ||
